In this issue:
Incurable locoregional SCC of the head and neck is a strong poor prognostic factor
Incidence trends of SCC of the head and neck in the aging population
KEYNOTE-629; pembrolizumab elicits rapid, durable anti-tumour activity in unresectable cSCC
Pembrolizumab improves healthrelated QoL in responders
Increased risk of cSCC after an AK diagnosis
Histopathologic upgrading of cSCC during Mohs micrographic surgery
High risk of cSCC in lung transplant recipients, especially if treated with voriconazole or azathioprine
Real-world effectiveness and safety of cemiplimab for advanced cSCC
Neoadjuvant immunotherapy promising for locoregionally advanced resectable cSCC
Adjuvant concurrent immunoradiotherapy for locally advanced cSCC
Please login below to download this issue (PDF)